ENVARSUS XR™ (tacrolimus extended-release tablets)
In August 2007, the FDA approved Fenoglide for the treatment of dyslipidemia in the United States. Veloxis has out-licensed the commercial rights of Fenoglide for the United States, Canada and Mexico.
The commercial rights are held by Valeant Pharmaceuticals International, Inc.
BUSINESS DEVELOPMENT CONTACT:
John Weinberg, EVP, CCO
Telephone: +1 732-321-3208
Dec 10, 2015
Veloxis announces change in management